idiopathic pulmonary fibrosis
Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease
June 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research
German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …
Boehringer launches IPF initiatives
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev
Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
Gilead terminates Phase II simtuzumab IPF study
January 6, 2016Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab
Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …
Roche says Esbriet shown to extend lives of IPF patients
September 30, 2015Medical Communications, Research and Development, Sales and Marketing Esbriet, Roche, idiopathic pulmonary fibrosis
Roche has presented new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF), showing …
Roche to present new Esbriet data at ERS Congress 2015
September 21, 2015Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone
Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …
Boehringer earns NICE nod for IPF drug Ofev
September 14, 2015Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis
NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …
Bristol-Myers Squibb makes big pharma deals
September 1, 2015Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis
Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …
InterMune’s IPF drug shines at ERS Congress
September 10, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone
InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …
IPF grabs headlines at American Thoracic Society conference
July 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing IPF, ats, ats 2014, brett wells, idiopathic pulmonary fibrosis, san diego, thoracic society
Just prior to landing in San Diego it was somewhat disconcerting to see fire spreading across the terrain and huge …
Boehringer and InterMune data on IPF drugs impress
May 19, 2014Research and Development, Sales and Marketing Boehringer Ingelheim, InterMune, idiopathic pulmonary fibrosis
Two new medicines for a generally fatal lung disease, known as idiopathic pulmonary fibrosis and made by Boehringer and InterMune, …
First idiopathic pulmonary fibrosis drug approved
March 4, 2011Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug
The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …
Gilead set to acquire Arresto for $225 million
December 23, 2010Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis
Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …
Latest content
FibroFind appoints Lee Borthwick as CEO
